Targeted Drug Regulation on Methylation of p53-BAX Mitochondrial Apoptosis Pathway Affects the Growth of Cholangiocarcinoma Cells

Journal of International Medical Research

Volumn 40, Issue 1, 2012, Pages 67-75

  Liu, Xiao Fang ^a   Jiang, H ^a   Zhang, C S ^a   Yu, S P ^a   Wang, Z Q ^a   Su, H L ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

5 Aza 2 Deoxycytidine; Apoptosis; Cholangiocarcinoma; Cyclin Dependent Kinase Inhibitor 2A (Cdkn2A); Death Associated Protein Kinase 1 (DAPK1); Gene Promoter; Methylation Specific Polymerase Chain Reaction; Pyd And Card Domain Containing (Pycard)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN BAX; PROTEIN P53;

APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL STRUCTURE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE INHIBITOR 2A GENE; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; DEMETHYLATION; FLOW CYTOMETRY; GENE; HUMAN; HUMAN CELL; MITOCHONDRION; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; PYD AND CARD DOMAIN CONTAINING GENE; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84863292056     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000107     Document Type: Article

References (32)

1. Havelka AM, Berndtsson M, Olofsson MH, et al: Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Rev Med Chem 2007; 7: 1035-1039.
2. Cheung HW, Jin DY, Ling MT, et al: Mitotic arrest deficient 2 expression induces chemo-sensitization to a DNA-damaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 2005; 65: 1450-1458.
3. Li J, Lee B, Lee AS: Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006; 281: 7260-7270.
4. Sherr CJ, Bertwistle D, den Besten W, et al: p53-dependent and-independent functions of the Arf tumor suppressor. Cold Spring Harb Symp Quant Biol 2005; 70: 129-137.
5. Schuler M, Green DR: Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001; 29: 684-688.
6. Liu XF, Zhang H, Zhu SG, et al: Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma. World J Gastroenterol 2006; 12: 4706-4709.
7. Claus R, Almstedt M, Lübbert M: Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol 2005; 32: 511-520.
8. Wang SG, Chen CH, Li DJ, et al: Effect of down regulation of laminin receptor on urokinasetype plasminogen activator expression in human bile duct carcinoma cells. Zhonghua Yi Xue Za Zhi 2004; 84: 1642-1644 [in Chinese, English abstract].
9. Liu XF, Zhu SG, Zhang H, et al: The methylation status of the TMS1/ASC gene in cholangiocarcinoma and its clinical significance. Hepatobiliary Pancreat Dis Int 2006; 5: 449-453.
10. Mosconi S, Beretta GD, Labianca R, et al: Cholangiocarcinoma. Crit Rev Oncol Hematol 2009; 69: 259-270.
11. Khan SA, Thomas HC, Davidson BR, et al: Cholangiocarcinoma. Lancet 2005; 366: 1303-1314.
12. Paik WH, Park YS, Hwang JH, et al: Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69: 55-62.
13. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15: 4240-4262.
14. Shaib YH, El-Serag HB, Nooka AK, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based casecontrol study. Am J Gastroenterol 2007; 102: 1016-1021.
15. Welzel TM, Graubard BI, El-Serag HB, et al: Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228.
16. Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125.
17. Dasanu CA, Majumder S, Trikudanathan G: Emerging pharmacotherapeutic strategies for cholangiocarcinoma. Expert Opin Pharmacother 2011; 12: 1865-1874.
18. Schiffman SC, Metzger T, Dubel G, et al: Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol 2011; 18: 431-438.
19. Ohtsuka T, Liu XF, Koga Y, et al: Methylationinduced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer. Oncogene 2006; 25: 1807-1811.
20. Riojas MA, Guo M, Glöckner SC, et al: Methylation-induced silencing of ASC/TMS1, a pro-apoptotic gene, is a late-stage event in colorectal cancer. Cancer Biol Ther 2007; 6: 1710-1716.
21. Suzuki H, Toyota M, Sato H, et al: Roles and causes of abnormal DNA methylation in gastrointestinal cancers. Asian Pac J Cancer Prev 2006; 7: 177-185.
22. Goel A, Nagasaka T, Arnold CN, et al: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007; 132: 127-138.
23. Karpinski P, Ramsey D, Grzebieniak Z, et al: The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 2008; 6: 585-591.
24. Xiong J, Epstein RJ: Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Mol Cancer Ther 2009; 8: 779-785.
25. Ishiguro M, Iida S, Uetake H, et al: Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 2007; 14: 1752-1762.
26. Liu LH, Xiao WH, Liu WW: Effect of 5-aza-2'-deoxycytidine on the P16 tumour suppressor gene in hepatocellular carcinoma cell line HepG2. World J Gastroenterol 2001; 7: 131-135.
27. Curtin K, Slattery ML, Samowitz WS: CpG island methylation in colorectal cancer: past, present and future. Patholog Res Int; 2011: 902674
28. Lujambio A, Esteller M: CpG island hypermethylation of tumour suppressor microRNAs in human cancer. Cell Cycle 2007; 6: 1455-1459.
29. Lujambio A, Calin GA, Villanueva A, et al: A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 13556-13561.
30. ARF is frequently observed in colorectal cancer with low-level microsatellite instability. J Int Med Res 2009; 37: 1038-1045.
31. Wijermans PW, Lübbert M, Verhoef G, et al: An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2d-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84(suppl 1): 9-17.
32. van den Bosch J, Lübbert M, Verhoef G, et al: The effects of 5-aza-2T-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 2004; 28: 785-790.